Editor’s Briefing: September 21, 2026

In Short. Monday’s tape is about challengers buying and dosing their way into franchises that already work—Telix paying $1.65 billion for ITM’s radioligand lane opposite Novartis, Alkermes taking orexin past narcolepsy into ADHD, Cue’s anti-IgE showing deeper hive clearance than Xolair’s arm, Beacon’s eye gene therapy clearing a pivotal after Biogen and J&J stumbled—while Lilly stacks Inluriyo with Verzenio and Merck’s Winrevair waits the same day for a recently diagnosed PAH label update.

---

Telix buys the radioligand neighbor

Telix Pharmaceuticals agreed to buy ITM Isotope Technologies Munich for $1.65 billion upfront, adding a lutetium-177 supply network and ITM-11, a radioligand therapy aimed at gastroenteropancreatic neuroendocrine tumors—the same commercial neighborhood as Novartis’s Lutathera. Up to $700 million more is milestone-tied, including $100 million if the FDA approves ITM-11 in a GEP-NET setting by the end of next year. That path is not clean: the agency rejected ITM-11 last month on chemistry, manufacturing and controls and a third-party plant inspection. Telix CEO Christian Behrenbruch cast the CRL as familiar territory after the company’s own Pixclara imaging agent, arguing the product profile is strong enough to refile. William Blair called the combined entity’s growth prospects “extremely bullish.” Telix already sells radioisotopes for prostate and brain imaging and is developing TLX591, a PSMA candidate that would face Novartis’s Pluvicto; ITM also supplies Lu-177 used in Pluvicto. Telix expects the combined company to generate about $1.3 billion this year on ITM’s 2025 sales base of $273 million. The deal is a vertical bet: own the isotope plant and the rival molecule, then argue differentiation rather than me-too. (Fierce Biotech; STAT+ title noted; full STAT+ body not opened)

Orexin leaves the sleep clinic

Alkermes reported a 50-adult phase 1b ADHD study of ALKS 7290, an orexin-receptor agonist, after Takeda’s Orzeyful opened the class in narcolepsy. Over two weeks, mean drops on the 54-point Adult ADHD Investigator Symptom Rating Scale were 14 points at 20 mg and 19 at 50 mg; Clinical Global Impressions severity scores moved from baselines of four and five toward one and two. The trial was not powered for formal efficacy tests. Common adverse events included dizziness, constipation, attention change, and the frequent urination already known to the class. A longer phase 2 with three dosing paradigms is already enrolling; pediatric work waits on more adult safety. CEO Blair Jackson called the broader ADHD market a potential “company changer” beside Alkermes’s sleep-franchise orexin alixorexton. The teachable point is mechanistic, not commercial yet: orexin’s arousal circuit is being asked to do cognitive work that stimulants and atomoxetine already own, with only early, uncontrolled-by-design numbers in hand. (Fierce Biotech; STAT+ title noted)

Anti-IgE, deeper and longer

Cue Biopharma’s partner Genesis Life Sciences said a China phase 2 of CUE-221 in chronic spontaneous urticaria hit its primary endpoint. Among 145 subjects, complete hive resolution on HSS7 at week 12 ran 43–54% across three CUE-221 doses versus 11% on placebo; a Xolair (omalizumab) reference arm posted 41% without planned statistical comparison. On UAS7 complete response, CUE-221 was 38–46% versus 11% placebo and 29% Xolair. Responses deepened after week 12: by week 28 the high-dose HSS7 resolution rate was 60% versus 24% on Xolair (lower doses closer to Xolair). Like omalizumab, CUE-221 neutralizes free IgE; Cue says the molecule also downregulates IgE production, which is the durability claim the week-28 gap is meant to support. A phase 2b/3 in CSU is next; food-allergy phase 2 planning continues after a July $50 million raise. Ascendant holds ex-China rights. Numerically ahead of Xolair is not the same as beating it in a head-to-head powered trial—Cue still has to run that study. (Fierce Biotech)

Second (and third) mover in the retina

Beacon Therapeutics’ phase 2/3 Vista study of laruparetigene zovaparvovec (laru-zova) in 85 males with X-linked retinitis pigmentosa met its primary endpoint: at 12 months, 24.1% (low dose) and 31% (high dose) gained ≥15 letters on a low-light eye chart; none of the controls did. Rolling BLA start is planned before year-end, with EU/UK filings and partner talks open for an ~80-person company. Biogen missed a retina-sensitivity primary in 2021; J&J’s maze-navigation phase 3 stumbled last year (MeiraGTx has since bought the asset back). Beacon’s construct packages a codon-stabilized full-length RPGR gene in a viral capsid for subretinal injection. CEO Lance Baldo’s lesson is textbook second-mover: borrow prior endpoint failures, pick a chart-based acuity measure patients and regulators already understand, and ship the gene form that lasts. (Fierce Biotech)

Lilly’s SERD combo; Europe’s CHMP slate

The FDA approved Lilly’s Inluriyo (imlunestrant) with Verzenio (abemaciclib) for previously treated ESR1-mutated ER+/HER2− breast cancer, expanding beyond Inluriyo monotherapy cleared nearly a year ago. Ember-3 showed median PFS of 11.1 months for the combo versus 5.5 months for Inluriyo alone (47% risk reduction). Lilly pitches waiting for clinical progression before switching—contrasting AstraZeneca’s Etcamah accelerated approval for earlier ESR1-mutation–triggered switches that need blood-based monitoring and a confirmatory trial after a 6–3 advisory vote against clinically meaningful benefit. Separately, Europe’s CHMP endorsed Novo’s Frehemgo (factor VIIIa-mimetic bispecific rivaling Roche’s Hemlibra) and AstraZeneca/Alexion’s self-injectable dual-binding nanobody C5 inhibitor Klygefa (gefurulimab) for generalized myasthenia gravis, plus a longer list of new and expanded opinions; it upheld a negative view of MaaT’s Xervyteg in acute graft-versus-host disease after reexamination. (Fierce Pharma; Fierce Pharma)

IPO window still open; capital footnotes

Eli Lilly–backed TRex Bio and hypertension play Retension Pharmaceuticals both filed IPO paperwork Friday without share counts or prices. TRex would fund phase 2 TNFR2 agonist TRB-061 in atopic dermatitis (phase 1 topline mid-2027) and a CD30 Treg agonist TRB-071 into healthy volunteers; Lilly signaled interest in participating. Retension would finish phase 2b of oral PDE-5 inhibitor RTN-001 in uncontrolled hypertension. That follows Electra’s $350 million IPO earlier in the week. BioPharma Dive’s Friday wrap also noted Ultragenyx pricing Fayuvi near $4 million after the Sanfilippo A gene-therapy approval already briefed Thursday. (Fierce Biotech; BioPharma Dive)

Policy / public-health sidebar

STAT News reports that addiction clinics are seeing a sharp rise in kratom and especially concentrated 7-hydroxymitragynine (7-OH) withdrawal. At telehealth clinic Boulder Care, kratom-related new patients rose from 3% in September 2025 to 8% in July 2026 and 14% in August; Massachusetts Recovery Centers of America sites that once saw ≤1 admission a week now see 10–20, treating severity “as if it’s fentanyl or oxycodone or heroin.” 7-OH acts directly on opioid receptors; FDA has flagged it as an emerging opioid threat and DEA has proposed threshold bans, with states already restricting access—clinicians suspect abrupt loss of supply is driving the surge. (STAT News)

BioSpace’s Monday features on Replimune’s Tudriqev and local cancer delivery, and on a Mikhail–Davis rare-disease regulatory framework, sit as context rather than overnight tape. (BioSpace)

What to watch

pdufa.bio (data through September 20) still lists Merck Winrevair (sotatercept) HYPERION—recently diagnosed pulmonary arterial hypertension label update—as Upcoming for September 21 (days-to-decision 0). Next: Mirum/Incyte zilurgisertib (FOP) September 26. Fayuvi / UX111 now shows Decided September 19 on the calendar (press approval was September 17). Inluriyo+Verzenio and Nuvalent zidesamtinib marked Decided September 18. Ameluz BCC and Scholar Rock Isembyld (apitegromab) remain Decided on the calendar against later goal dates still circulating in secondary packet lists. Mim8 (denecimig) still Upcoming without a clean date on the public calendar slice. October: Roche Tecentriq adjuvant MSI-H/stage III colon (October 9), Merck/Daiichi I-DXd ES-SCLC (October 10), Roche Enspryng TED (October 15), Viatris/Opus MR-141 phentolamine ophthalmic (October 17). BioProcess International’s Boston conference runs September 22–25; overnight BPI hard-news was thin beyond Sanofi’s $661 million Fluzone High-Dose facility inauguration in Toronto (still pending regulatory approval before commercial vaccine production) and Merck KGaA’s Bengaluru life-science hub expansion. (pdufa.bio; BioProcess International)

Open mechanism questions from this tape: whether radioligand CRLs on CMC are truly recoverable at Telix–ITM scale before Novartis’s installed base digs in; whether orexin agonists can move cognition without becoming poorly tolerated stimulants-by-another-name; whether IgE-production downregulation (Cue) survives a powered Xolair head-to-head; whether low-light letter gains in XLRP (Beacon) translate into daily function and durable BLA packages after maze/sensitivity failures elsewhere; whether Ember-3’s wait-for-progression SERD logic or Serena-6’s early-switch logic wins the ESR1 commercial argument; and whether Winrevair’s HYPERION label update, if it lands today, moves sotatercept meaningfully earlier in PAH without rewriting the risk–benefit already known from later-line use.